Impact of prior cancer history on survival in brain malignancy: A propensity score-adjusted, population-based study
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Prior cancer history (PCH) generally does not impact brain cancer survival. However, specific prior cancers (gastrointestinal, hematologic/lymphatic) and glioblastoma may affect overall survival outcomes.
Area Of Science
- Oncology
- Clinical Epidemiology
Background
- Prior cancer history (PCH) often leads to exclusion from clinical trials.
- Evidence suggests PCH does not adversely affect cancer patient outcomes.
- Survival impact of PCH on brain cancer patients is largely unknown.
Purpose Of The Study
- To determine the prevalence of PCH in brain cancer patients.
- To assess the impact of PCH on overall survival (OS) and brain cancer-specific survival (BCSS).
Main Methods
- Retrospective cohort study using SEER database (2000-2019).
- Included patients with brain cancer as first or second primary malignancy.
- Propensity Score Matching (PSM) and survival analyses (Kaplan-Meier, Cox models) were employed.
Main Results
- 2.78% of 42,726 brain cancer patients had PCH.
- PCH was a significant risk factor for OS (AHR 1.26, p<.001) but not BCSS (AHR 0.97, p=.54).
- Prior gastrointestinal and hematologic/lymphatic malignancies significantly impacted OS.
Conclusions
- PCH generally does not significantly affect brain cancer patient survival.
- Exceptions include prior gastrointestinal or hematologic/lymphatic malignancies.
- Glioblastoma histology also impacts survival outcomes.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...